- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.03. | Incyte's JAK inhibitor cream Opzelura shows promise in hidradenitis suppurativa | ||
| 12.03. | Pfizer's Velsipity receives MHRA and NICE authorisations to treat ulcerative colitis | ||
| 12.03. | UCB presents positive long-term results for bimekizumab in hidradenitis suppurativa | ||
| 12.03. | Sanofi shares promising results for amlitelimab in moderate-to-severe atopic dermatitis | ||
| 12.03. | University of Liverpool reveals new framework to tackle antimicrobial resistance in UK | ||
| 11.03. | Ipsen's Cabometyx and BMS' Opdivo recommended by NICE for advanced kidney cancer | ||
| 11.03. | J&J and Protagonist's JNJ-2113 shown to maintain skin clearance in plaque psoriasis | ||
| 11.03. | Valneva's chikungunya virus vaccine recommended by US CDC advisory committee | ||
| 11.03. | Gilead shares positive real-world data for COVID-19 treatment Veklury in hospitalised patients | ||
| 11.03. | Pipeline puzzle: US Inflation Reduction Act | ||
| 08.03. | Bristol Myers Squibb's Opdivo combination receives FDA approval for urothelial carcinoma | ||
| 08.03. | MHRA approves UCB's Rystiggo to treat generalised myasthenia gravis | ||
| 08.03. | BeiGene's Brukinsa granted FDA accelerated approval for advanced follicular lymphoma | ||
| 08.03. | AstraZeneca announces plans to invest £650m in UK to boost life sciences sector | ||
| 08.03. | New nanoparticle to deliver vaccines and generate strong immune responses at lower dose | ||
| 08.03. | Achieving patient-guided drug development: keeping the patient experience a priority | ||
| 07.03. | Gilead and Merus announce oncology partnership worth over $1.5bn | ||
| 07.03. | GSK announces positive results for Blenrep in head-to-head multiple myeloma study | ||
| 07.03. | Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease | ||
| 07.03. | AstraZeneca/Daiichi Sankyo's Enhertu not recommended by NICE for advanced breast cancer | ||
| 07.03. | Ipsen promotes Ioana Parsons to general manager for UK and Ireland | ||
| 07.03. | AI and over-digitalisation | ||
| 06.03. | Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti | ||
| 06.03. | Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m | ||
| 06.03. | Sanofi's Xenpozyme not recommended by NICE for ultra-rare disease ASMD |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
